miR-295-3P antagomir
miR-295-3P antagomir has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Feb 6, 2026: “Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction”.
1 paper studies it1 findingUpdated
See all 1 papers on miR-295-3P antagomir
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
- 1 lab in 1 country
- Funders: Beijing Municipal Natural Science Foundation and 4 more
- Animals1
What did studies of miR-295-3P antagomir find?
1Studies of miR-295-3P antagomir measured one outcome, heart failure with preserved ejection fraction.
Heart failure with preserved ejection fraction
downin mice1
1 study
Heart failure with preserved ejection fraction
downin mice1
miR-295-3P antagomir decreases heart failure with preserved ejection fraction in HFpEF mice.
“MiR-295-3p antagomir treatment mitigated HFpEF phenotypes.”
Animalsin HFpEF miceheartmales
Cardiovascular research